Visuals
Sidebar
The Distribution of New Cases in the US has Shifted
The distribution of new cases in the US has shifted from the Northeast to the Southern and Western states. Pink ...
Projected Demand for Hospital Resources in Early 2021
Demand for hospital resources are likely to increase by the end of January 2021 - with a distinctly sharper rate ...
Aggregated COVID-19 Forecasts for November, 2020
The CDC received forecasts of COVID-19 deaths over the next 4 weeks in November from 47 modeling groups. Of the ...
Sensible Medicine
Sensible medicine is an approach to treatment that seeks a balance along the spectrum of the strength of evidence and ...
Value Creation in VC Funds
PVC, a sort of funds of funds when it comes to venture capital funds, has beautifully captured a value creation ...
IHME Extends COVID-19 Projections to February 2021
Researchers at the University of Washington’s Institute for Health Metrics and Evaluation (IHME) released new numbers, updating its COVID-19 death toll forecast ...
The Value of Universal Masking
Universal masking at Mass General Hospital was associated with a significantly lower rate of SARS-CoV-2 positivity among health care workers. ...
Causal Reasoning Improves Medical Diagnosis
As the development of medicine accelerates in the age of COVID-19, the methods and processes through which we conduct the ...
The Sharpe Ratio
The Sharpe Ratio is used to help investors predict the anticipated financial return relative to the risk of an investment. ...
FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation
Clinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...
Read morePopular
-
Optimizing Semaglutide Therapy: When to Add Other Peptides like Sermorelin and Enhancing Bioavailability with Multiple Forms
-
The Generic That Isn’t
-
Patients Searching Symptoms Online: How To Respond With Care
-
The Pros and Cons of Teletherapy for Patients and Providers
-
Reducing Chemical Risk in Pathology Labs
